Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma

Table 2

Univariate analysis of prognostic factors for patients with lung adenocarcinoma in Henan, China, 2017.

Factor	Person-years	Cases	Case fatality rate (%)	HR^1	95% CI^2	value
Total	421.3	233	55.3
Age
<65	263.7	129	48.9	1.00
≥65	157.7	104	65.9	1.37	1.05–1.78	0.019
Sex
Man	201.8	120	59.5	1.00
Women	219.5	113	51.5	0.87	0.67–1.12	0.280
TNM^3 stage
I–III	228.9	85	37.1	1.00
IV	192.5	148	76.9	2.16	1.65–2.82	<0.001
KPS^4 scores
≥80	269.5	115	42.7	1.00
<80	151.8	118	77.7	1.88	1.45–2.43	<0.001
Lung lobectomy
Yes	172.2	49	28.5	1.00
No	249.1	184	73.9	2.78	2.02–3.83	<0.001
Chemotherapy
Yes	248.4	117	47.1	1.00
No	173.0	116	67.1	1.48	1.14–1.91	0.003
Radiotherapy
Yes	71.6	32	44.7	1.00
No	349.7	201	57.5	1.33	0.92–1.94	0.132
Smoking
No	260.2	138	53.0	1.00
Yes	161.1	95	59.0	1.09	0.84–1.42	0.500
Alcohol
No	382.9	200	52.2	1.00
Yes	38.5	33	85.7	1.69	1.17–2.45	0.006
Family history
No	385.9	218	56.5	1.00
Yes	35.4	15	42.4	0.73	0.43–1.24	0.248
Hemoglobin^5
NPHb	367.1	189	51.5	1.00
LPHb	54.3	44	81.0	1.61	1.16–2.24	0.004

¹HR: hazard ratio by multivariate Cox proportional hazards regression. ²CI: confidence interval. ³TNM: tumor-node-metastasis. ⁴KPS: Karnofsky performance status. ⁵Hemoglobin: NPHb (normal pretreatment hemoglobin): men 120–160 g/l and women 110–150 g/l; LPHb (low pretreatment hemoglobin): men < 120 g/l and women ≤ 110 g/l.